Metered dose inhaler therapy for asthma, bronchitis, and emphysema

Area of Science:

• Pulmonology
• Pharmacology
• Respiratory Medicine

Background:

• Metered dose inhalers (MDIs) are crucial for aerosol therapy in asthma, bronchitis, and emphysema.
• Physician prescribing patterns often deviate from optimal MDI therapy guidelines.
• MDIs are increasingly recognized as more efficient and cost-effective than jet nebulizers in healthcare settings.

Purpose of the Study:

• To review the current use of MDIs in aerosol therapy for obstructive airway diseases.
• To evaluate the efficacy and cost-effectiveness of MDIs compared to alternative delivery methods.
• To highlight optimal prescribing practices and patient-specific treatment adjustments for MDI use.

Main Methods:

• Literature review of studies on MDI use in asthma, bronchitis, and emphysema.
• Analysis of prescribing patterns and treatment outcomes associated with MDI therapy.
• Evaluation of drug classes available for MDI administration and their effectiveness.

Main Results:

• MDIs are suitable for all classes of aerosolized drugs.
• Improved patient outcomes are associated with proper MDI technique and adjusted dosages.
• Aerosol glucocorticoids are recommended as first-line therapy for asthma, but their role in bronchitis and emphysema requires further investigation.
• While MDI drugs for asthma haven't been proven to increase mortality, potential toxicity warrants further research.

Conclusions:

• MDIs represent an efficient and cost-effective method for aerosol therapy, potentially replacing jet nebulizers.
• Optimizing MDI technique and medication dosage can enhance treatment effectiveness for patients.
• Aerosol glucocorticoids are a cornerstone of asthma management, with ongoing research into their broader applications and safety profiles.